Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet (London, England). 26 juill 2008;372(9635):293‑9. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/18657708
Antiretroviral Therapy Cohort Collaboration (ART-CC), Mugavero MJ, May M, Harris R, Saag MS, Costagliola D, et al. Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice? AIDS. 30 nov 2008;22(18):2481‑92. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/19005271
Bhaskaran K, Hamouda O, Sannes M, Boufassa F, Johnson AM, Lambert PC, et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA. 2 juill 2008;300(1):51‑9. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/18594040
Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group, Sabin CA, Smith CJ, d’Arminio Monforte A, Battegay M, Gabiano C, et al. Response to combination antiretroviral therapy: variation by age. AIDS. 31 juill 2008;22(12):1463‑73. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/18614870
Grabar S, Lanoy E, Allavena C, Mary-Krause M, Bentata M, Fischer P, et al. Causes of the first AIDS-defining illness and subsequent survival before and after the advent of combined antiretroviral therapy. HIV Med. avr 2008;9(4):246‑56. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/18366449
Guiguet M, Mary-Krause M, Ename B, Costagliola D, Grabar S. Influence of control selection in nested case-control studies: the example of exposure to antiretroviral treatment (ART) and the risk of myocardial infarction (MI) in the French Hospital Database on HIV (FHDH-ANRS CO4). Pharmacoepidemiol Drug Saf. mai 2008;17(5):468‑74. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/18324608
Guiguet M, Porter K, Phillips A, Costagliola D, Babiker A. Clinical progression rates by CD4 cell category before and after the initiation of combination antiretroviral therapy (cART). Open AIDS J. 19 févr 2008;2(1):3‑9. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/18923700
Harris RJ, Sterne JAC, Abgrall S, Dabis F, Reiss P, Saag M, et al. Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. Antivir Ther. 2008;13(8):959‑67. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/19195321
Jarrin I, Geskus R, Bhaskaran K, Prins M, Perez-Hoyos S, Muga R, et al. Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women. Am J Epidemiol. 1 sept 2008;168(5):532‑40. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/18663213
Kousignian I, Abgrall S, Grabar S, Mahamat A, Teicher E, Rouveix E, et al. Maintaining antiretroviral therapy reduces the risk of AIDS-defining events in patients with uncontrolled viral replication and profound immunodeficiency. Clin Infect Dis. 15 janv 2008;46(2):296‑304. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/18171266
Mouala C, Houzé S, Guiguet M, Abboud P, Pialoux G, Viget N, et al. Imported malaria in HIV-infected patients enrolled in the ANRS CO4 FHDH study. J Acquir Immune Defic Syndr. 1 sept 2008;49(1):55‑60. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/18667929
Pantazis N, Touloumi G, Vanhems P, Gill J, Bucher HC, Porter K, et al. The effect of antiretroviral treatment of different durations in primary HIV infection. AIDS. 30 nov 2008;22(18):2441‑50. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/19005267
Piketty C, Selinger-Leneman H, Grabar S, Duvivier C, Bonmarchand M, Abramowitz L, et al. Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. AIDS. 19 juin 2008;22(10):1203‑11. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/18525266
Selinger-Leneman H, Matheron S, Mahamat A, Moreau J, Costagliola D, Abgrall S, et al. Dual nucleoside reverse transcriptase inhibitor therapy in the combination antiretroviral therapy era and predictors of discontinuation or switch to combination antiretroviral therapy. J Acquir Immune Defic Syndr. 1 févr 2008;47(2):206‑11. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/17971717
Touloumi G, Pantazis N, Stirnadel HA, Walker AS, Boufassa F, Vanhems P, et al. Rates and determinants of virologic and immunological response to HAART resumption after treatment interruption in HIV-1 clinical practice. J Acquir Immune Defic Syndr. 15 déc 2008;49(5):492‑8. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/18989233
